BCAX (Bicara Therapeutics) Liabilities-to-Assets : 0.07 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BCAX Bicara Therapeutics Inc BCAX
12 GF Score
Price $27.83
! 3 Warning Signs
View Full Analysis

What is Bicara Therapeutics Liabilities-to-Assets?

Bicara Therapeutics BCAX -0.93% 12 Liabilities-to-Assets is 0.07 as of Mar. 2026. GuruFocus rates BCAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Bicara Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $39.64 Mil. Bicara Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $553.60 Mil. Therefore, Bicara Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 was 0.07.

Bicara Therapeutics  (NAS:BCAX) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Bicara Therapeutics Liabilities-to-Assets Related Terms

Bicara Therapeutics Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Bicara Therapeutics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics Liabilities-to-Assets Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Liabilities-to-Assets
15.74 1.64 0.04 0.07

Bicara Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.05 0.07 0.07

BCAX vs ZYME, SRPT, INVA: Liabilities-to-Assets Comparison

For the Biotechnology subindustry, Bicara Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics Liabilities-to-Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's Liabilities-to-Assets falls into.


BCAX
12GF Score
Bicara Therapeutics Inc BCAX
Liabilities-to-Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicara Therapeutics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Bicara Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:

Liabilities-to-Assets (A: Dec. 2025 )=Total Liabilities/Total Assets
=29.542/430.994
=0.07

Bicara Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 is calculated as

Liabilities-to-Assets (Q: Mar. 2026 )=Total Liabilities/Total Assets
=39.641/553.599
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 0.07 mean?
Bicara Therapeutics (BCAX) has a Liabilities-to-Assets of 0.07 as of Mar. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Bicara Therapeutics and its competitors.
Is Bicara Therapeutics' Liabilities-to-Assets too high?
Bicara Therapeutics' current Liabilities-to-Assets is 0.07. Overall, Bicara Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' Liabilities-to-Assets compare to ZYME and SRPT?
Bicara Therapeutics' Liabilities-to-Assets of 0.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Bicara Therapeutics and its competitors. Bicara Therapeutics's current Liabilities-to-Assets is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current Liabilities-to-Assets of 0.07. The current Liabilities-to-Assets is 0.07. Bicara Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current Liabilities-to-Assets is 0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bicara Therapeutics Business Description

Address 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
12GF Score

Get the complete analysis for BCAX

Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.83
Price